Chroma Medicine and Nvelop Therapeutics today announced their merger and subsequent launch of nChroma Bio (“nChroma” or “the company”) to redefine the future of genetic medicines. nChroma brings together potent epigenetic editing plus non-viral, programmable delivery to address key limitations in the field and expand the scope of treatable diseases. The merger results in an industry-leading company with a deeply experienced team. Jeff Walsh will serve as nChroma’s CEO and Jeff Marrazzo will serve as nChroma’s Chairman of the Board.
We congratulate Jonathan Weissmann and Luke Gilbert, the UCSF founders.